RetaMaps

Hamilton Health & Wellness Associates

Hamilton Health & Wellness Associates · 1255 Whitehorse Mercerville Road · Hamilton Township, NJ 08619

5.0· 64 Google reviews

Listing updated October 2, 2026

Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

About this practice

Hamilton Health & Wellness Associates is a gynecology and wellness practice in Hamilton Township, New Jersey. Its website describes gynecology, hormone, metabolic, functional and aesthetic care centered on Dr. Samra-Latif Estafan, who it says has a gynecology foundation, dual board certifications in anti-aging and regenerative medicine and aesthetic medicine, and more than 20 years of experience. The site also discusses hunger signaling, insulin response and sleep in relation to weight. On Google it has a 5.0-star rating across 64 reviews dating back to 2018, none in the past year; reviewers mention the staff and caring treatment, three each.

Services & access

Advertises semaglutide todayNot listed
Advertises tirzepatide todayNot listed
Telehealth visitsNot listed
Cash pay accepted—
Accepts insurance — per practice websiteYes
Accepting new patients — per practice websiteYes

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Review activity

★ 5.0
Google rating · 64 reviews

Counts computed by RetaMaps from public Google reviews; most recent review 2024-06-12. Read the reviews themselves on the practice's Google listing.

What patients say

Rated ★5.0 across 64 Google reviews. Of the 8 reviews we analyzed, 8 (100%) are positive (4–5★) and 0 (0%) are negative (1–2★).

What patients like

  • Friendly, helpful staff3 reviews
  • Feeling listened to3 reviews
  • Knowledgeable, professional providers2 reviews

Common complaints

No negative reviews among those we analyzed.

5★
8
4★
0
3★
0
2★
0
1★
0

Most recent Google reviews

Judy G.★★★★★2024-06-12

Dr. Samra-Latif is an excellent doctor!! I had been searching for quite some time for a doctor that could address my specific issues with menopause. Dr. Latif was recommended to me and I am so happy that she was! I have finally found a doctor that will listen, is caring and is especially knowledgeable in the area of menopause. In addition, all of her staff is extremely friendly and willing to help you in any way that they can. I am so glad that I am feeling like my old self again and it's all thanks to her.

Beth★★★★★2024-05-21

This is a wonderful practice. Dr. Omnia takes the time to see what works best for the patient. Everyone is friendly, caring, and goes above and beyond. Would highly recommend!!

Ashley C.★★★★★2024-03-01

I had an amazing experience with Dr. Omnia. Her bedside manor, professional behavior and overall attention to detail made me feel comfortable throughout my appointment. She was very friendly and made sure I was confident and happy each step of the way. I highly recommend her and her office for any health and wellness needs!

Carolyn G.★★★★★2018-08-31

I don’t know where I would be without you Dr. Latif! Your kindness, patience and understanding makes it so easy to talk to you. I finally found a doctor who listens, understands and gets to why of the issues and not just throw medication at the issue. Thank you from the bottom of my heart for all you do for me and all your patients!

Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.

Nearby providers in Hamilton Township

Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs